Overview

A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment

Status:
Completed
Trial end date:
2012-11-28
Target enrollment:
Participant gender:
Summary
This study is to assess the effect of renal function on the efficacy and safety of ASP1941 in type 2 diabetic patients with mild to moderate renal impairment.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Ipragliflozin